Ionis Pharmaceuticals (IONS) News Today $33.65 +0.87 (+2.65%) Closing price 04:00 PM EasternExtended Trading$33.40 -0.25 (-0.74%) As of 05:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Analysts Just Made A Sizeable Upgrade To Their Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) ForecastsMay 5 at 11:04 AM | uk.finance.yahoo.comAllostery Investments LP Invests $2.27 Million in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Allostery Investments LP bought a new stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund bought 65,000 shares of the company's stock, valued atMay 4 at 7:45 AM | marketbeat.comBlueCrest Capital Management Ltd Buys Shares of 26,200 Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)BlueCrest Capital Management Ltd purchased a new stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm purchased 26,200 shares of the company's stock, valued at approximately $916,0May 3 at 8:09 AM | marketbeat.comPDT Partners LLC Grows Stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)PDT Partners LLC boosted its holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 116.4% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 28,994 shares of the company's stock after purchasing an additional 15May 3 at 6:00 AM | marketbeat.comSchonfeld Strategic Advisors LLC Has $12.98 Million Stock Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Schonfeld Strategic Advisors LLC increased its stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 2.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 371,381 shares of the coMay 3 at 5:53 AM | marketbeat.comMichael R. Hayden Acquires 15,000 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) StockMay 3 at 5:13 AM | insidertrades.comIonis Pharmaceuticals (NASDAQ:IONS) Shares Gap Up on Earnings BeatIonis Pharmaceuticals (NASDAQ:IONS) Shares Gap Up After Strong EarningsMay 2 at 10:27 AM | marketbeat.comHsbc Holdings PLC Invests $2.93 Million in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Hsbc Holdings PLC purchased a new stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 83,055 shares of the company's stock, valued at approxiMay 2 at 4:35 AM | marketbeat.comTower Research Capital LLC TRC Increases Stock Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Tower Research Capital LLC TRC raised its holdings in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 229.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 14,157 shares of the company's stoMay 2 at 4:15 AM | marketbeat.comIonis Pharmaceuticals (NASDAQ:IONS) Shares Gap Up After Earnings BeatMay 2 at 1:11 AM | americanbankingnews.com7IONS : The Analyst Verdict: Ionis Pharmaceuticals In The Eyes...May 1, 2025 | benzinga.comIonis Pharmaceuticals Inc (IONS) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ...May 1, 2025 | finance.yahoo.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Purchased by Stifel Financial CorpStifel Financial Corp boosted its position in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 15.9% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 211,493 shares of the company's stock after buying an additional 28,98May 1, 2025 | marketbeat.comIonis Pharmaceuticals misses Q1 revenue estimates, raises full-year outlookApril 30, 2025 | investing.comIonis Pharmaceuticals, Inc. (IONS) Q1 2025 Earnings Call TranscriptApril 30, 2025 | seekingalpha.comSusquehanna Fundamental Investments LLC Invests $7.45 Million in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Susquehanna Fundamental Investments LLC bought a new stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 213,015 shares of the company's stock, valueApril 30, 2025 | marketbeat.comAdage Capital Partners GP L.L.C. Sells 225,000 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Adage Capital Partners GP L.L.C. lowered its stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 45.0% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 275,000 shares of the company'April 30, 2025 | marketbeat.comIonis Pharmaceuticals Q1 2025 Earnings PreviewApril 29, 2025 | msn.comAquatic Capital Management LLC Makes New Investment in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Aquatic Capital Management LLC purchased a new stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) in the fourth quarter, according to its most recent 13F filing with the SEC. The fund purchased 230,016 shares of the company's stock, valued at approximately $8,041,000. AquatiApril 29, 2025 | marketbeat.comPrice T Rowe Associates Inc. MD Decreases Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Price T Rowe Associates Inc. MD decreased its position in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 9.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 3,826,939 shares of theApril 29, 2025 | marketbeat.comRaymond James Financial Inc. Purchases Shares of 105,619 Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Raymond James Financial Inc. purchased a new stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 105,619 shares of the company's stock, valued at approximately $April 29, 2025 | marketbeat.comGhisallo Capital Management LLC Cuts Stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Ghisallo Capital Management LLC cut its holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 75.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 100,000 shares of the company's stockApril 28, 2025 | marketbeat.comSyon Capital LLC Takes Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Syon Capital LLC bought a new position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 10,119 shares of the company's stock, valued at approximately $354,000. AApril 28, 2025 | marketbeat.comNatixis Takes Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Natixis acquired a new stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 16,626 shares of the company's stock,April 27, 2025 | marketbeat.comCanada Pension Plan Investment Board Purchases 8,700 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Canada Pension Plan Investment Board boosted its position in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 77.7% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 19,900 shares of the company's stock after puApril 27, 2025 | marketbeat.comCommerce Bank Sells 63,969 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Commerce Bank lessened its stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 82.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 13,584 shares of the company's stock after selling 63,969 shares during theApril 26, 2025 | marketbeat.comIonis Pharmaceuticals (IONS) Expected to Announce Quarterly Earnings on WednesdayIonis Pharmaceuticals (NASDAQ:IONS) will be releasing its Q1 2025 earnings before the market opens on Wednesday, April 30. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-4-30-ionis-pharmaceuticals-inc-stock/)April 25, 2025 | marketbeat.comEversept Partners LP Has $7.52 Million Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Eversept Partners LP trimmed its holdings in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 54.4% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 214,952 shares of the company's stock after selling 256,403 shares during the period. IonisApril 24, 2025 | marketbeat.comIonis Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:IONS)Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Get Free Report) was the recipient of unusually large options trading activity on Monday. Traders bought 5,610 call options on the company. This is an increase of approximately 1,252% compared to the typical volume of 415 call options.April 23, 2025 | marketbeat.comIonis: Potentially A Great Time To Buy Ahead Of Q1 Earnings (Upgrade)April 22, 2025 | seekingalpha.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Stock Holdings Raised by Capital World InvestorsCapital World Investors lifted its stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 46.5% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 11,465,413 shares of the company's stock after purchasing an additional 3,637,041April 22, 2025 | marketbeat.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Sold by Jump Financial LLCJump Financial LLC cut its holdings in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 98.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 39,737 shares of the company's stock after sellingApril 22, 2025 | marketbeat.comMarshall Wace LLP Sells 1,108,158 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Marshall Wace LLP decreased its position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 57.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 812,306 shares of the company's stock after selling 1,108,158April 21, 2025 | marketbeat.comRenaissance Technologies LLC Purchases 15,000 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Renaissance Technologies LLC raised its stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 7.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 205,514 shares of the company's stock aftApril 21, 2025 | marketbeat.comQ1 EPS Forecast for Ionis Pharmaceuticals Lowered by AnalystIonis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) - Stock analysts at Leerink Partnrs lowered their Q1 2025 earnings per share estimates for shares of Ionis Pharmaceuticals in a research note issued to investors on Wednesday, April 16th. Leerink Partnrs analyst M. Foroohar now forecasts thaApril 20, 2025 | marketbeat.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Receives Average Recommendation of "Moderate Buy" from BrokeragesIonis Pharmaceuticals, Inc. (NASDAQ:IONS - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the twenty ratings firms that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, six haveApril 20, 2025 | marketbeat.comWilliam Blair Issues Positive Forecast for IONS EarningsIonis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) - Research analysts at William Blair increased their Q1 2025 earnings estimates for shares of Ionis Pharmaceuticals in a note issued to investors on Monday, April 14th. William Blair analyst M. Minter now expects that the company will earn (April 19, 2025 | marketbeat.comInsider Selling: Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Sells 680 Shares of StockApril 18, 2025 | insidertrades.comIonis Pharmaceuticals (NASDAQ:IONS) Receives Buy Rating from Needham & Company LLCNeedham & Company LLC reiterated a "buy" rating and issued a $60.00 price target on shares of Ionis Pharmaceuticals in a research note on Tuesday.April 17, 2025 | marketbeat.comIonis to hold first quarter 2025 financial results webcastApril 17, 2025 | finance.yahoo.comGranite Investment Partners LLC Has $2.58 Million Holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Granite Investment Partners LLC decreased its stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 13.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 73,866 shares of the company's stocApril 16, 2025 | marketbeat.comTD Cowen Sticks to Their Buy Rating for Ionis Pharmaceuticals (IONS)April 15, 2025 | markets.businessinsider.comKennedy Capital Management LLC Boosts Stock Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Kennedy Capital Management LLC increased its position in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 37.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 223,278 sApril 13, 2025 | marketbeat.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Acquired by Geode Capital Management LLCGeode Capital Management LLC lifted its stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 0.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 2,687,248 shares of the company's stock after purchasing an additional 18,890April 13, 2025 | marketbeat.comQ1 Earnings Forecast for IONS Issued By HC WainwrightIonis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) - HC Wainwright issued their Q1 2025 earnings estimates for Ionis Pharmaceuticals in a note issued to investors on Monday, April 7th. HC Wainwright analyst M. Kapoor forecasts that the company will earn ($1.04) per share for the quarter. HCApril 12, 2025 | marketbeat.comMorgan Stanley Keeps Their Hold Rating on Ionis Pharmaceuticals (IONS)April 11, 2025 | markets.businessinsider.comIonis Pharmaceuticals price target lowered to $52 from $55 at Morgan StanleyApril 11, 2025 | markets.businessinsider.comIonis Pharmaceuticals (NASDAQ:IONS) Upgraded by HC Wainwright to "Strong-Buy" RatingHC Wainwright upgraded Ionis Pharmaceuticals to a "strong-buy" rating in a research note on Monday.April 11, 2025 | marketbeat.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Sold by Landscape Capital Management L.L.C.Landscape Capital Management L.L.C. lessened its stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 59.6% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 10,270 shares of the company's stock after selling 15,165 shares during the quarter. LandscApril 10, 2025 | marketbeat.comIonis Pharmaceuticals (NASDAQ:IONS) Hits New 12-Month Low - Should You Sell?Ionis Pharmaceuticals (NASDAQ:IONS) Reaches New 1-Year Low - Here's What HappenedApril 9, 2025 | marketbeat.com Get Ionis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for IONS and its competitors with MarketBeat's FREE daily newsletter. Email Address IONS Media Mentions By Week IONS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IONS News Sentiment▼1.130.72▲Average Medical News Sentiment IONS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IONS Articles This Week▼278▲IONS Articles Average Week Get Ionis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for IONS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies BIIB News Today UTHR News Today BMRN News Today INCY News Today EXEL News Today NBIX News Today EXAS News Today RGEN News Today HALO News Today MDGL News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IONS) was last updated on 5/5/2025 by MarketBeat.com Staff From Our PartnersWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredMost traders are panicking. We’re cashing inMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredWhat President Trump’s Executive Order 14154 means for your moneyNearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a f...Stansberry Research | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ionis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ionis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy IONS Stock Free IONS Stock Alerts